Cargando…
Current status of first‐line treatment with pembrolizumab for non–small‐cell lung cancer with high PD‐L1 expression
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum‐based chemotherapy (COMB) should be selected for patients with advanced non–small‐cell lung cancer (NSCLC) exhibiting high PD‐L1 expression (tumor proportion score ≥ 50%). We performed a retrospective, multicente...
Autores principales: | Ikezawa, Yasuyuki, Mizugaki, Hidenori, Morita, Ryo, Tateishi, Kazunari, Yokoo, Keiki, Sumi, Toshiyuki, Kikuchi, Hajime, Kitamura, Yasuo, Nakamura, Atsushi, Kobayashi, Maki, Aso, Mari, Kimura, Nozomu, Yoshiike, Fumiaki, Furuta, Megumi, Tanaka, Hisashi, Sekikawa, Motoki, Hachiya, Tsutomu, Nakamura, Keiichi, Shimokawa, Mototsugu, Oizumi, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207363/ https://www.ncbi.nlm.nih.gov/pubmed/35377496 http://dx.doi.org/10.1111/cas.15361 |
Ejemplares similares
-
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
por: Yamamoto, Gaku, et al.
Publicado: (2021) -
γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer
por: Mizugaki, H, et al.
Publicado: (2012) -
Delayed local reaction at a previous injection site reaction with dupilumab
por: Sumi, Toshiyuki, et al.
Publicado: (2021) -
Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Sumi, Toshiyuki, et al.
Publicado: (2021) -
Successful management of severe bronchial asthma exacerbated by anti‐PD‐L1 treatment: A report of two cases
por: Sumi, Toshiyuki, et al.
Publicado: (2021)